Breaking News
0

Astellas Pharma Inc (ALPMY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
16.59 -0.01    -0.03%
15/11 - Closed. Currency in USD ( Disclaimer )
After Hours
16.58
-0.01
-0.06%
15:57:52 - Delayed Data
Type: Equity
Market: United States
ISIN: US04623U1025 
S/N: 04623U102
  • Volume: 14,912
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 16.55 - 16.74
START TRADING NOW
| AD | 75% of retail investor accounts lose money when trading spread bets and CFDs with this provider
Astellas Pharma Inc 16.59 -0.01 -0.03%
START TRADING NOW
| AD | 75% of retail investor accounts lose money when trading spread bets and CFDs with this provider

ALPMY Financial Summary

 
A brief financial summary of Astellas Pharma Inc as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

For the six months ended 30 September 2019, Astellas Pharma Inc revenues increased 1% to Y650.47B. Net income applicable to common stockholders increased 24% to Y128.53B. Revenues reflect Sales of Pharmaceuticals-Americas-XTANDI segment increase of 19% to Y46.91B, Sales of Pharmaceuticals-Estabridge-XTANDI segment increase of 14% to Y33.6B.

TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

ALPMY Income Statement

Gross margin TTM 77.75%
Operating margin TTM 19.63%
Net Profit margin TTM 17.25%
Return on Investment TTM 15.65%
 Total Revenue  Net Income
Period Ending: Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018
Total Revenue 316336 334134 301320 357932
Gross Profit 247976 263622 236981 273761
Operating Income 85110 77086 34541 82529
Net Income 70010 58518 30730 87670

ALPMY Balance Sheet

Quick Ratio MRQ 1.44
Current Ratio MRQ 1.77
LT Debt to Equity MRQ 10.37%
Total Debt to Equity MRQ 13.85%
 Total Assets  Total Liabilities
Period Ending: Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018
Total Assets 1979816 1927031 1897648 1928325
Total Liabilities 683681 677323 639252 636116
Total Equity 1296135 1249708 1258396 1292209

ALPMY Cash Flow Statement

Cash Flow/Share TTM 151.6
Revenue/Share TTM 684.09
Operating Cash Flow  21.02%
 Cash  Net Change in Cash
Period Ending: Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018
Period Length: 6 Months 3 Months 12 Months 9 Months
Cash From Operating Activities 101659 7412 256899 201844
Cash From Investing Activities -46553 -13985 -41757 -28461
Cash From Financing Activities -45956 -40354 -233681 -173340
Net Change in Cash 293 -51652 -20657 -435
* In Millions of JPY (except for per share items)
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ALPMY Comments

Write your thoughts about Astellas Pharma Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email